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Advances in cystic fibrosis management have significantly improved life expectancy in these patients. However, we are now faced
withagrowingnumberoflong-termextrapulmonaryconsequencesofthisdisease,includingophthalmiccomplicationsofdiabetes
in cystic fibrosis patients. We present a unique report that documents a case of diabetic papillopathy progressing to nonarteritic
anteriorischemicopticneuropathyresultinginvisionlossinapatientwithCFanddiabetes.Ithighlightsthepotentiallydevastating
consequences of longstanding diabetes in CF patients.
1. Introduction
Cystic fibrosis-related diabetes (CFRD) is a well-known
complication of cystic fibrosis (CF) and is often diagnosed
in early adulthood [1]. With recent increases in patient sur-
vival, ophthalmic complications of diabetes are beginning to
emerge.Toourknowledge,wereportthefirstcaseofdiabetic
papillopathy (DP) in a CF patient, which was complicated
bynonarteriticanteriorischemicopticneuropathy(NAION)
and permanent vision loss. We report this unique case to
draw attention to the clinical presentation of this potential
ophthalmic complication of diabetes in CF patients.
2. Case Presentation
Wepresenta37-year-oldwomanwithmoderate-to-severeCF
l u n gd i s e a s es i n c et h ea g eo f5 .S h ew a sd i a g n o s e dw i t hd i a -
betes at a different institution, when she presented with mild
DKA at 24 years of age. Her specific diabetes diagnosis was
ambiguous due to a paucity of information available to our
center, as well as poor recollection of events. Her c-peptide
was 408 one month after her diagnosis with diabetes, and
subsequentlyshewastreatedasCFRD.Herc-peptidebecame
undetectable 4 years after her initial diabetes diagnosis. She
hasbeensuboptimallycontrolledonamultipledailyinjection
(MDI) regimen with insulin glargine and insulin lispro. She
has also been using carbohydrate counting and correction
factor insulin dosing. Her hemoglobin A1C was consistently
between 8.7 and 11.2%. Her diabetes was difficult to control
d u et ov a r i a b l en u t r i t i o n a li n t a k e ,h y p o g l y c e m i aa n dt h ef e a r
of such, and resistance to proper monitoring. Her history
was significant for left-eye diabetic retinopathy identified on
fundoscopicscreening,pancreaticexocrineinsufficiency,and
microalbuminuria.
She presented with a two-day history of sudden-onset
severe bilateral headache, periorbital pain, and pressure,
followed by a superior visual field deficit involving her left
eye. On physical exam, she was normotensive. There was
no evidence of focal neurological deficits. Fundoscopic
examination revealed bilateral optic disc swelling (Figure 1).2 Case Reports in Endocrinology
(a) (b)
Figure 1: Bilateral diabetic papillopathy. (a) Fundus photo of the right eye showing an edematous and hyperaemic optic disc. Note the
peripapillary circumferential retinal striae extending towards the macula signifying subretinal fluid secondary to leakage from the disc. (b)
Concurrent fundus photo of the left eye. Significant disc edema is also present. Note the relative pallor of this optic disc compared to that of
the right eye suggesting permanent optic nerve damage and chronicity.
Her best-corrected vision was normal at 20/25 on the right
and 20/20 on the left. Automated visual field testing showed
a ne n l a r g e db l i n ds p o ti nt h er i g h te y ea n dad e n s es u p e r i o r
altitudinal defect in the left eye. Fluorescein angiogram
demonstrated a mild delay in arteriovenous phase and
diabetic microaneurysms bilaterally.
Due to her presentation with optic disc swelling and
headache, she underwent a CT scan of the head and lumbar
puncture to rule out raised intracranial pressure, which were
both normal. MRI of the orbits and brain was also normal.
With other potential causes of optic disc swelling being
ruled out, she was eventually diagnosed with diabetic papil-
lopathy (DP) causing vessel compression with subsequent
nonarteritic anterior ischemic optic neuropathy (NAION).
She underwent bilateral intraocular steroid injections in an
attempt to reduce the swelling.
Over the course of the next month, she experienced
subtle improvementin her left eye superior visual field defect
b u td e v e l o p e dr e d u c e dv i s u a la c u i t ya n dar e l a t i v ea ff e r e n t
pupillary defect of the right eye with an inferior altitudinal
visual field deficit. Her visual acuity deteriorated to 20/200
on the right but remained 20/20 on the left. The optic
disc swelling on the left improved compared to before, but
the right disc remained edematous with venous congestion;
flame hemorrhages and cotton wool spots were also present
suggestive of retinal infarcts. With her deteriorating vision,
she received a prolonged course of systemic steroids as well
as intraocular bevacizumab (Avastin) injections.
Over several months, her vision worsened in a step-
wise fashion corresponding to subsequent CF exacerbations
a n dc o n c u r r e n tp o o rg l y c e m i cc o n t r o la n dt h e ns t a b i l i z e d .
On her last ophthalmologic exam 7 months after diagnosis,
her vision was 20/60 on the right and 20/100 on the left
with bilateral disc pallor. Her Goldmann visual field testing
revealed a slightly worse right inferior altitudinal defect and
a stable left superior altitudinal, with fundi showing optic
atrophy.
3. Discussion
CFRD is the most common comorbidity in patients with
CF, occurring in approximately 40–50% of adults with CF
[1]. CFTR dysfunction leads to the inspissation of thick
secretionswithinthepancreaticducts,causinginflammation,
obstruction, and destruction of the pancreas [1]. CFRD
results from both insulin insufficiency from destruction of
beta cells in the pancreas as well as insulin resistance from
uncontrolled infections. There are relatively few publications
that specifically address CFRD complications, and rare oph-
thalmic complications such as diabetic papillopathy have
never been described in this population.
Diabetic papillopathy (DP) is an ophthalmic complica-
tion of diabetes that has been described in the literature
through case reports and case series over the past 30 years.
The pathogenesis of this disease remains unclear. The most
p o p u l a rt h e o r ys u g g e s t st h a tD Pi sr e v e r s i b l ei s c h e m i ao ft h e
prelaminar and inner surface layers of the optic nerve head
and therefore represents a milder form of NAION [2]. DP is
believedtobeaseparateentityfromdiabeticretinopathy,and
although the latter is usually present in patients with DP, its
severity tends to vary [2]. Major risk factors for DP include
presence of diabetes, a high hemoglobin A1C, and small cup-
to-discdiameterratio.Adrasticallyreducedlevelofglycemia
inresponsetointensifiedinsulintreatmenthasbeenreported
as a possible inciting factor [3].
ThemostcommonlyacceptedcriteriafordiagnosisofDP
includepresenceofdiabetes,opticdiscedema,relativelymild
opticnerve dysfunction,and absence of ocular inflammation
or raised intracranial pressure. Patients tend to complain of
mild visual impairment, most commonly without pain or
neurological symptoms. Patients with NAION, on the other
hand, tend to complain of visual loss, either sudden onset,
or a decline of vision over days, with occasional periorbital
pain and most commonly altitudinal visual field defects. The
optic disc is hyperemic and edematous, which may be diffuseCase Reports in Endocrinology 3
or segmental. Intraocular pressure tends to be normal. Focal
regions of swelling may be seen but may not correlate with
the sector of visual field loss [2].
In DP, optic disc edema tends to resolve within 2–10
months, leaving minimal optic atrophy and minimal visual
field loss. Visual acuity tends to return to baseline in most
patients, while in others, visual impairment persists because
of maculopathy. If there is concomitant evidence of NAION
aswaspresentinourpatient,improvementofDPonlyoccurs
in approximately 30% of cases. Under this scenario, visual
acuity and visual field deficits tend to stabilize after several
months.
Th e r ea r en op r o v e ne ff e c t i v et h e r a p i e sf o rD Pa n d
NAION, and no controlled trials are available. Trials of
periocular steroids have demonstrated a shortened duration
of DP, thought to be due to angiostatic and antioedema
effects at the level of the optic nerve [4]. Other case reports
have shown positive results after intraocular injections of
anti-VEGF agents such as bevacizumab (Avastin) [5]. Some
clinicians advocate systemic corticosteroids in patients with
DP to prevent progression to NAION; however, studies have
not shown benefit in these patients [2]. Our patient was
treated with systemic and intraocular steroids, as well as
intraocular Avastin. Unfortunately, her vision deteriorated
despite these therapies, highlighting a need for improved
therapies for this condition.
Our patient was diagnosed and treated as CFRD for
many years primarily on the basis of a positive c-peptide
measured soon after her initial presentation, as well as due
to the historical transmission of such diagnosis through the
various institutions where she was treated. Interestingly, our
patient’s c-peptide became undetectable 4 years after her
initialdiagnosis,whichismoreconsistentwithtype1diabetes
as are her rapid progression from normal glucose tolerance
to mild DKA in absence of CF exacerbation and initially
normal pancreatic exocrine function. However, Kessler and
colleagues have reported that baseline c-peptide levels in
CFRD patients may be undetectable even in patients with
negative GAD antibodies [6]. In addition, CF patients have
been shown to have a blunted response to hyperglycemia
based on their c-peptide in Moran et al.’s paper [7]. From
the available data, our CF patient may have either CFRD or
type 1 diabetes, as autoantibody testing for diabetes mellitus
is not routinely performed at our center. The uncertainties
regarding our patient’s diabetes classification only came
to light upon a more in-depth examination of her initial
presentation for this report, and we suspect that there are
likely other CF patients considered to have CFRD when
in fact, their classification may not be so clear. Therefore,
regardless her underlying pathophysiology, as she represents
the first case of DP reported in a CF patient, we believe that
her history is noteworthy.
This unique case of a patient with CF and diabetes who
developed features of DP progressing to NAION highlights
the potentially devastating consequences of longstanding
diabetes. With further advances in the life expectancy of CF
patients, we expect the incidence of ophthalmic complica-
t i o n so fd i a b e t e si nC Fp a t i e n t st or i s e ,a n dt h e r e f o r ea w a r e -
ness of the early clinical presentation of DP is paramount.
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